Professor Lip, MD, is an academic clinical cardiologist based in a busy city centre teaching hospital and leads a large, multidisciplinary research group (including clinical and laboratory-based components).
He is also Visiting Professor of Haemostasis Thrombosis and Vascular Sciences in the School of Life & Health Sciences at the University of Aston in Birmingham, England.
Professor Lip is Adjunct Professor in Cardiovascular Sciences at Aalborg University, Denmark. Furthermore, he is Visiting Professor of Cardiology at Belgrade University, Serbia. In 2014, he was conferred Honorary Professor in Department 1 of Geriatric Cardiology, Nanlou Division, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing, China.
Half of his time is spent as a clinician, and he practises the full range of cardiovascular medicine, including outpatient clinics, with large atrial fibrillation and hypertension specialist clinics, and coronary care units. He also undertakes coronary intervention and assists in a 24/7 primary angioplasty rota for ST elevation MIs.
As an academic, Professor Lip provides strategy and research direction for his group, with many local, national, and international collaborations in progress. He has had a major interest into the epidemiology of atrial fibrillation (AF), as well as the pathophysiology of thromboembolism in this arrhythmia. Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification. The CHA2DS2-VASc and HAS-BLED scores for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into major international management guidelines.
His work into improving AF clinical management won the Heart Rhythm UK‘ Arrhythmia Alliance Team of the Year Award 2012'
In addition, he awarded the BMJ Group Awards ‘Cardiovascular Team of the Year 2013’
In April 2013, Professor Lip was conferred an honorary doctorate (Doctor Medicinae Honoris Causa) from Aalborg University
Professor Lip was also selected to the Thomson Reuters Science Watch list of “Who and What was Hot in Scientific Research in 2012” (issued June 2013) which lists the most influential scientific researchers and research papers of the year.
In June 2014, he also listed amongst the year’s Thomson Reuters Science Watch list of Hottest Researchers of 2013, and was the only cardiologist on the list.
In June 2014, he was listed as a Highly Cited Researcher, which represents some of the world’s most influential scientists whose work has been consistently judged by their peers to be of particular significance, being the top 1% most cited for their subject field and year of publication [issued June 2014]. Professor Lip was one of the 4 named Birmingham academics on this list [see press release].
In January 2014, Professor Lip was ranked by Expertscape as the world's leading expert in the understanding and treatment of AF, and correspondingly, the University of Birmingham listed as the world's top institution for AF research [see Expertscape press release]
In May 2014, Professor Lip was also ranked by Expertscape as amongst the top 10 of the world's leading experts in the understanding and treatment of hypertension [see Expertscape press release]
Professor Lip is a member of the European Heart Rhythm Association (EHRA) and Chairs its scientific documents committee (2013-). He serves on the board of the Working Group on Thrombosis of the European Society of Cardiology (ESC). He is a member of the Working Group on Cardiovascular Pharmacology of the ESC, and is also a member of the European Association of Percutaneous Coronary Revascularisation.
Professor Lip has acted as Clinical Adviser for the UK National Institute for Health & Clinical Excellence (NICE) guidelines on atrial fibrillation (AF) management (2006), and part of the Guideline Development Group for the 2014 NICE guidelines on AF. He was also on the writing committee for the 8th American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as various guidelines and/or position statements from EHRA including the EHRA statement on defining endpoints for AF management and EHRA guidelines for antithrombotic therapy during ablation.
He has acted as Chair for task forces, writing a EHRA/Working Group on Thrombosis Position Statement on Bleeding Risks in Atrial Fibrillation Patients (2011), as well as joint consensus document of the ESC Heart Failure Association and Working Group Thrombosis on Thromboembolism and Antithrombotic Therapy for Heart Failure in Sinus Rhythm (2012).
Professor Lip was Chairman of the Task Force which developed and launched a new EHRA patient information webpage (www.afibmatters.org), launched June 2013.
He was also on the writing committee of the 2010 ESC Guidelines on Atrial Fibrillation, the 2012 ESC Focussed Update Guidelines on Atrial Fibrillation, and the 2012 ESC Guidelines on Heart Failure. He was Deputy Editor (“content expert”) for the 9th ACCP guidelines on antithrombotic therapy for AF (2012).
Professor Lip has acted as Senior Editor for major international textbooks [eg, Lip GYH, Hall JE (eds) Comprehensive Hypertension. Mosby 2007] and Section Editor on hypertension (eg, Crawford, DiMarco, Paulus Cardiology, now in 3rd edition), as well as contributed to major textbooks [eg, the European Textbook of Cardiovascular Medicine (chapter on atrial fibrillation that serves as the core curriculum for ESC cardiology trainees), and Crawford’s Cardiology textbook chapter on atrial fibrillation, etc.
Professor Lip is involved at the senior editorial level for major international journals, including Thrombosis & Haemostasis (Editor-in-Chief, Clinical Studies - Impact Factor 6.094); Europace (Associate Editor); and Circulation (Guest Editor).
Under his editorship, Thrombosis and Haemostasis was winner of the Thomson Reuters ScholarOne Journal Triathlon, an international award given to the publication which shows efficiency, longevity and validation of submissions (issued December 2013):
h-index 117 [Google Scholar, accessed June 2014]
1786 citations on Medline, a selection are as follows:
Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY. Renal impairment and ischaemic stroke risk assessment in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol. 2013 May 21;61(20):2079-87
Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73.
Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke. 2013 May;44(5):1329-36.
Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012 May 30;344:e3522.
Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012 Nov 5;345:e7097. doi:10.1136/bmj.e7097.
Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012 May 15;125(19):2298-307. Epub 2012 Apr 18.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500-10.
Apotolakis S, Lane D, Gao Y, Buller H, Lip GY. Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study. J Am Coll Cardiol 2012;60:861-7
Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012;60:738-46
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel ris score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80.
Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY; Italian AT-500 Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011 Jun;42(6):1768-70.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100.
Olesen J, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. N Engl J Med 2012;367:625-35.
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124. PubMed PMID: 21282258
Lip GY, Tse HF, Lane DA. Seminar – Management of atrial fibrillation. Lancet 2012;379(9816):648-61
Banerjee A, Marín F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke. 2011 Nov;42(11):3316-22.
Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011 Mar 22;57(12):1339-48.
Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol. 2010 Sep 7;56(11):827-37.
Guidelines and Consensus Documents
Lip GY, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, Marin F, Lane DA. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail. 2012 May 19. [Epub ahead of print] PubMed PMID: 22611046.
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e531S-75S.
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011 Nov 30;106(6):997-1011.
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F; Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010 Jun;31(11):1311-8.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429.
Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):546S-592S.